Poland· PL-100456091

Desferal

A deferoxamine product containing deferoxamini mesilas, registered in Poland by InPharm Sp. z o.o.. The same ATC class is registered in 16 of our 19 countries.

ATC V03AC01

Checked against URPL (Poland) on September 27, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about deferoxamini mesilasAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Deferoxamine is registered in 16 of 19 countries.

Countries holding a registration under ATC V03AC01 (deferoxamine), each read from that country’s own register.

This record: Poland, from URPL (Poland)
10 of them publish a price we can compare per daily dose

Search deferoxamine products by name

Deferoxamine · ATC V03AC01

16 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Italyprice
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of deferoxamine costs, country by country.

Normalised to the WHO defined daily dose (2.8 g), so markets compare like for like.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Deferoxamine · price per daily dose (2.8 g)

USD · FX 28 Sept 2026

CH Switzerland$48.38
FR France$33.66

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)

Active substance: Deferoxamini mesilas
Manufacturer: InPharm Sp. z o.o.
Country: Poland (PL)
ATC code: V03AC01
ATC class: Deferoxamine
Defined daily dose: 2.8 g, P
Reimbursed: Not published by this register
Source register: URPL (Poland)
Last checked: September 27, 2026

Packs & prices · 1

gtin
05909991462192

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

49 interactions on record for deferoxamine.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check deferoxamine against other medicines How interaction checks work

Deferoxamine · interactions on record

49 records

9 severe
5 moderate
35 info

Most severe, free to view

CidofovirJ05AB12severe
VigabatrinN03AG04severe
InotersenN07XX15severe
IopamidolV08AB04severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Deferoxamine in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All deferoxamine products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

Austria · Desferal
Belgium · Desferal
Bulgaria · Десферал
Cyprus · Deferoxamine Noridem
Czechia · Desferal
Germany · Deferoxaminmesilat Noridem Enterprises, Desferal
Denmark · Desferal
Spain · Desferin
Finland · Desferal
France · Desferal
United Kingdom (Northern Ireland) · Desferrioxamine Mesilate Noridem Enterprises
Greece · Deferoxamine Noridem, Demoferidon
Hungary · Desferal
Ireland · Desferal
Iceland · Desferal
Italy · Deferoxamina Noridem, Desferal
Luxembourg · Desferal
Netherlands · Desferal
Norway · Desferal
Portugal · Desferal
Romania · Desferal
Sweden · Desferal

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/de670124-afc0-4dd4-8dc9-5405c55114bd
GET /v1/drugs/de670124-afc0-4dd4-8dc9-5405c55114bd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania roztworu do wstrzykiwań",
  "source": "urpl",
  "strength": "500 mg",
  "packaging": "05909991462192 ¦ Rp ¦ 141424\n10 fiol.",
  "substance": "Deferoxamini mesilas 500 mg",
  "common_name": "Deferoxamini mesilas",
  "pl_product_id": "100456091",
  "pozwolenie_nr": "285/21",
  "auth_procedure": "IR",
  "authorisation_validity": "2026-08-05"
}

API reference MCP server Plans

See everything about deferoxamine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console